SCHEMBL1703478

SCHEMBL1703478

Nc1n[nH]c2cncc(-c3ccc(NC(=O)Nc4cccc(Cl)c4)cc3)c12

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDR P35968 20/20 1.00
▸ KIT P10721 14/20 0.79
▸ FLT3 P36888 14/20 0.79
▸ LCK P06239 8/20 0.78
▸ CSF1R P07333 8/20 0.78
▸ FLT1 P17948 8/20 0.78
▸ FLT4 P35916 8/20 0.78
▸ LYN P07948 7/20 0.78
▸ BLK P51451 7/20 0.78
▸ SRC P12931 6/20 0.78
▸ FYN P06241 5/20 0.78
▸ ABL1 P00519 4/20 0.78
▸ VHL P40337 1/20 0.68
▸ NTRK1 P04629 2/20 0.62
▸ PLK4 O00444 2/20 0.62
▸ AURKA O14965 2/20 0.62
▸ ROCK2 O75116 2/20 0.62
▸ INSR P06213 2/20 0.62
▸ MET P08581 2/20 0.62
▸ FGFR1 P11362 2/20 0.62

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL421753 0.89 KDR (1.00) KDRKITFLT3LCKCSF1R
SCHEMBL233874 0.88 KDR (1.00) KDRKITFLT3LCKCSF1R
SCHEMBL1703302 0.87 KDR (0.79) KDRKITFLT3LCKCSF1R
SCHEMBL1703142 0.83 KDR (1.00) KDRKITFLT3LCKCSF1R
SCHEMBL1703314 0.82 KDR (1.00) KDRKITFLT3LCKCSF1R
SCHEMBL12346328 0.82 KDR (0.72) KDRKITFLT3LCKCSF1R
SCHEMBL1703080 0.80 KDR (0.74) KDRKITFLT3LCKCSF1R
SCHEMBL420530 0.80 KDR (0.73) KDRKITFLT3LCKCSF1R
SCHEMBL422656 0.80 KDR (0.69) KDRKITFLT3LCKCSF1R
SCHEMBL423364 0.80 KDR (0.76) KDRKITFLT3LCKCSF1R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1807424-B1 NOVEL KINASE INHIBITORS ABBOTT LAB (US) 2012-04-18 — — EP claimed
EP-1807424-A2 NOVEL KINASE INHIBITORS ABBOTT LABORATORIES (US) 2007-07-18 — — EP claimed
US-20060178378-A1 Novel kinase inhibitors ABBVIE INC. 2006-08-10 — — US claimed
WO-2006050109-A2 NOVEL KINASE INHIBITORS ABBOTT LABORATORIES (US) 2006-05-11 — — WO claimed
EP-1807424-B1 NOVEL KINASE INHIBITORS ABBOTT LAB (US) 2012-04-18 — — EP disclosed
US-7812166-B2 Kinase inhibitors ABBOTT LABORATORIES (US) 2010-10-12 — — US disclosed
EP-1807424-A2 NOVEL KINASE INHIBITORS ABBOTT LABORATORIES (US) 2007-07-18 — — EP disclosed
US-20060178378-A1 Novel kinase inhibitors ABBVIE INC. 2006-08-10 — — US disclosed
WO-2006050109-A2 NOVEL KINASE INHIBITORS ABBOTT LABORATORIES (US) 2006-05-11 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060178378-A1 Novel kinase inhibitors ABL1, MAP3K19, MAP3K20 KDR 434/4885KIT 426/4885FLT3 79/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback